Faculty profile
Richard Liggins
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Pharmacokinetics of small hyperbranched polyglycerols as an osmotic agent for peritoneal dialysis: Plasma exposure, organ distribution and excretion in rats.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis · 2023
Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes.
Diabetes, obesity & metabolism · 2023
Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.
Endocrinology · 2021
Latest funding
- $160,000
Preclinical Development of a Novel Organ Transplant Solution
CIHR · 2014 · Principal investigator
- $289,799
Preclinical Development of a Glucose-Free Peritoneal Dialysis Solution
CIHR · 2014 · Principal investigator
- $294,600
Intravesical Docetaxel Formulation for the Treatment of Ta/T1 Stage Bladder Cancer
CIHR · 2013 · Co-investigator
16 publications.
Pharmacokinetics of small hyperbranched polyglycerols as an osmotic agent for peritoneal dialysis: Plasma exposure, organ distribution and excretion in rats.
Du C, Jayo R, Mendelson AA, Chafeeva I, Roza GD, Liggins R, Kizhakkedathu JN
Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes.
Hoffman EG, D'Souza NC, Aiken J, Atherley S, Liggins R, Riddell MC
Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.
Hoffman EG, Jahangiriesmaili M, Mandel ER, Greenberg C, Aiken J, D'Souza NC, Pasieka A, Teich T, Chan O, Liggins R, Riddell MC
Transcriptome analysis of signaling pathways of human peritoneal mesothelial cells in response to different osmotic agents in a peritoneal dialysis solution.
Liu B, Feng S, Dairi G, Guan Q, Chafeeva I, Wang H, Liggins R, da Roza G, Kizhakkedathu JN, Du C
Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes.
Pandey R, Jackson JK, Liggins R, Mugabe C, Burt HM
Peritoneal and Systemic Responses of Obese Type II Diabetic Rats to Chronic Exposure to a Hyperbranched Polyglycerol-Based Dialysis Solution.
La Han B, Guan Q, Chafeeva I, Mendelson AA, da Roza G, Liggins R, Kizhakkedathu JN, Du C
Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing.
Shen Y, Zeglinski MR, Turner CT, Raithatha SA, Wu Z, Russo V, Oram C, Hiroyasu S, Nabai L, Zhao H, Bozin T, Westendorf K, Kopko I, Huang R, Arns S, Tan J, Zeng H, Boey A, Liggins R, Jaquith J, Cameron DR, Papp A, Granville DJ
Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder.
Pandey R, Jackson JK, Mugabe C, Liggins R, Burt HM
Corrigendum to "Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay" [Bioorg. Med. Chem. Lett. 25 (2015) 2505-2509].
Arns S, Tan J, Sun S, Galey A, Zisman N, Ross F, Udechukwu J, Dercho S, Gusti V, Paquette J, Wennekes T, Webb M, Bourque E, Withers SG, Liggins R
Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
Tai SH, Agafitei O, Gao Z, Liggins R, Petric M, Withers SG, Niikura M
Preclinical Development of a Novel Organ Transplant Solution
Principal investigators: Du, Caigan; Brooks, Donald E; Kizhakkedathu, Jayachandran N; Liggins, Richard T; Nguan, Christopher
Keywords: Colloid; Donor Organ Preservation; Kidney Transplantation; Organ Cold Storage; Organ Perfusion; Organ Preservation Solution; Pharmacokinetics; Pig Model; Rat Model; Transplantation
Preclinical Development of a Glucose-Free Peritoneal Dialysis Solution
Principal investigators: Kizhakkedathu, Jayachandran N; Du, Caigan; Liggins, Richard T
Keywords: Bicompatible Polymer; End-Stage Renal Disease; Hyperbranched Polyglycerol; Kidney Diseases; Kidney Function; Metabolism; Non-Glucose Dialaysis Solution; Ostmotic Agent; Peritoneal Dialysis; Tolerance Studies
Intravesical Docetaxel Formulation for the Treatment of Ta/T1 Stage Bladder Cancer
Principal investigators: Burt, Helen M
Keywords: Advanced Formulation; Anticancer Drugs; Bladder Cancer; Drug Delivery Systems; Hyperbranched Polymers; Intravesical Chemotherapy; Mucoadhesion; Nanoparticles; Safety And Toxicology; Tissue Penetration And Distribution
Intravesicular nanoparticulate drug delivery systems for application in bladder cancer
Principal investigators: Burt, Helen M; Bally, Marcel B; Brooks, Donald E; Gleave, Martin E; Minchinton, Andrew I
Keywords: Anticancer Drugs; Bladder Cancer; Blood And Tissue Distribution; Drug Delivery Systems; Hyperbranched Polymers; Mucoadhesion; Nanoparticles
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Urologic Sciences
- Molecular Biology and Biochemistry
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.